Search for a trial

A prospective, observational, multi-centre study investigating alterations of gut microbiome with its subsequent interaction on the brain-immune-intestine axis in patients with active relapsing remitting Multiple Sclerosis who start with oral treatment.

Primary Objective: To determine if the (change in) gut and oral microbiome at baseline or in the first 3 months after start of Cladribine is a predictor for treatment response in subjects with active relapsing remitting MS.The secondary objectives…